Francisco Cervantes

Publicacions destacades

• Does ruxolitinib prolong the survival of patients with myelofibrosis?

  Autors:

  Cervantes F; Pereira A ;

  Referència: Blood 2017.

• Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response

  Autors:

  Cervantes, Francisco; Correa, Juan-Gonzalo; Perez, Isabel; Garcia-Gutierrez, Valentin; Redondo, Sara;

  (...)

  Jimenez-Velasco, Antonio; Steegmann, Juan-Luis; Sanchez-Guijo, Fermin; Ferrer-Marin, Francisca; Pereira, Arturo.

  Veure llistat complet d'autors

  Referència: Annals Of Hematology 2017.

• Alleviating Anemia and Thrombocytopenia in Myelofibrosis Patients

  Autors:

  Cervantes F; Correa JG; Hernandez-Boluda JC ;

  Referència: Plos One 2016.

• Accurately assessing risk in your myeloproliferative neoplasm patient

  Autors:

  Cervantes F; Pereira A;

  Referència: 2016.

• Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results

  Autors:

  Cervantes, F; Isola, IM; Correa, JG; Pereira, A; Alvarez-Larrán, A;

  Hernández-Boluda, JC.

  Referència: Annals Of Hematology 2015.

• ESSENTIAL THROMBOCYTHEMIA IN YOUNG PATIENTS: RISK/ BENEFIT OF THE ANTI PLATELET THERAPY ACCORDING TO THE MUTATIONAL STATE OF JAK2V617F AND CALR

  Autors:

  Larran, AA; Besses, C; Rodrigo, EA; Cervantes, F; Boluda, JCH;

  (...)

  Andreasson, B; Casares, MTG; Antelo, ML; Xicoy, B; Mata, MI.

  Veure llistat complet d'autors

  Referència: Haematologica 2015.

• What we can do about anemia in myelofi-brosis

  Autors:

  Cervantes F; Pereira A;

  Referència: 2015.

• Leucemia mieloide crónica

  Autors:

  Francisco Cervantes Requena;

  Referència: 2015.

• How I treat myelofibrosis

  Autors:

  Cervantes, Francisco;;

  Referència: Blood 2014.

• GENDER DIFFERENCES AND MPN SYMPTOM BURDEN: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)

  Autors:

  Cervantes; F;

  Referència: Haematologica 2014.